Digest Network Come funziona
Network
/
Società
LT
Non verificato

LTZ Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Scienza
Medicina - Varie
Biologia
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Industria
LTZ Doses First Participant in Phase 1/1b Trial of LTZ-232 for mCRC and Other Solid Tumors
Fonte
LTZ Therapeutics
Emittente
Business Wire
1.00
0
07/07/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Industria
LTZ Therapeutics Announces FDA Clearance of IND Application for LTZ-232 to Treat Advanced Metastatic Colorectal Cancer and Other Solid Tumors
Fonte
LTZ Therapeutics
Emittente
Business Wire
1.00
0
06/05/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
LTZ Therapeutics Raises $38 Million in Support of Advancing Myeloid Engager Immunotherapy Pipeline
Fonte
LTZ Therapeutics
Emittente
Business Wire
1.00
0
29/07/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases
Fonte
LTZ Therapeutics
Emittente
Business Wire
1.00
0
24/02/2025
Biotecnologia
Farmaceutica
Sanità
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
Fonte
LTZ Therapeutics
Emittente
Business Wire
1.00
0
30/07/2024
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline
Fonte
LTZ Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0